ReviewEuropean journal of pharmacology2021
Brief review on repurposed drugs and vaccines for possible treatment of COVID-19.
Review in European journal of pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 43 citations in OpenAlex.
- Exploring the key structural attributes and chemico-biological interactions of pyridinone-based SARS-CoV-2 3CLHeliyon · 2024Article
- Integrating Quantum Mechanics into Protein-Ligand Docking: Toward Higher Accuracy and Reliability.Research square · 2024Article
- Docking Studies and Molecular Dynamics Simulations of Potential Inhibitors from the Brown SeaweedBiotech (Basel (Switzerland)) · 2023Article
- Supervised Machine Learning Models to Identify Early-Stage Symptoms of SARS-CoV-2.Sensors (Basel, Switzerland) · 2022Article
- When a Neglected Tropical Disease Goes Global: Knowledge, Attitudes and Practices of Italian Physicians towards Monkeypox, Preliminary Results.Tropical medicine and infectious disease · 2022Article
- Regulation of IFNα-induced expression of the short ACE2 isoform by ULK1.Molecular immunology · 2022Article
- Transient production of receptor-binding domain of SARS-CoV-2 in Nicotiana benthamiana plants induces specific antibodies in immunized mice.Molecular biology reports · 2022Article
- Molnupiravir: A lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2-A narrative review.Journal of medical virology · 2022Review
- Social Media and COVID-19-Perceptions and Public Deceptions of Ivermectin, Colchicine and Hydroxychloroquine: Lessons for Future Pandemics.Antibiotics (Basel, Switzerland) · 2022Article
- Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Review
- Iran's Struggling Health System in the Policy of Managing the COVID-19 Pandemic.International journal of preventive medicine · 2022Article
- Non-clinical safety assessment and in vivo biodistribution of CoviFab, an RBD-specific F(ab')2 fragment derived from equine polyclonal antibodies.Toxicology and applied pharmacology · 2022Article
- Selinexor and COVID-19: The Neglected Warden.Frontiers in pharmacology · 2022Review
- Time to 'Mind the Gap' in novel small molecule drug discovery for direct-acting antivirals for SARS-CoV-2.Current opinion in virology · 2021Review
- Nano-biofortification of different crops to immune against COVID-19: A review.Ecotoxicology and environmental safety · 2021Review
- How can we accelerate COVID-19 vaccine discovery?Expert opinion on drug discovery · 2021Article
- A focus on the spread of the delta variant of SARS-CoV-2 in India.The Indian journal of medical research · 2021Article
- Biologics for Psoriasis During the COVID-19 Pandemic.Frontiers in medicine · 2021Review
- Repurposing of Drugs for SARS-CoV-2 Using Inverse Docking Fingerprints.Frontiers in chemistry · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of the pandemic coronavirus disease 2019 (Covid-19) has claimed more than a million lives. Various in silico, in vitro, and in vivo studies are being conducted to understand the effect of SARS-CoV-2 on the cellular metabolism of humans and the various drugs and drug-targets that may be used. In this review, we discuss protein-protein interactions (PPIs) between viral and human proteins as well as viral targets like proteases. We try to understand the molecular mechanism of various repurposed antiviral drugs against SARS-CoV-2, their combination therapies, drug dosage regimens, and their adverse effects along with possible alternatives like non-toxic antiviral phytochemicals. Ultimately, randomized controlled trials are needed to identify which of these compounds has the required balance of efficacy and safety. We also focus on the recent advancements in diagnostic methods and vaccine candidates developed around the world to fight against Covid-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.